Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2024

Open Access 10-04-2024 | Neuroendocrine Tumor | REVIEW

Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors

Authors: Denise S. Hoogenkamp, Linda J. de Wit–van der Veen, Daphne M. V. Huizing, Margot E. T. Tesselaar, Rachel S. van Leeuwaarde, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Arthur J. A. T. Braat

Published in: Current Oncology Reports | Issue 5/2024

Login to get access

Abstract

Purpose of Review

To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.

Recent Findings

Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery.

Summary

There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.
Literature
1.
Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35:e13309.PubMedCrossRef
2.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. JCO. 2023;41:5049–67.CrossRef
3.
Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683–99.PubMedCrossRef
4.
Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA, et al. Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis. JAMA Oncol. 2019;5:480–9.PubMedPubMedCentralCrossRef
5.•
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. Final results of the NETTER-1 trial highlight the impact of PRRT as treatment for patients with advanced NETs.)PubMedCrossRef
6.
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.PubMedPubMedCentralCrossRef
7.
Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25:4012.PubMedPubMedCentralCrossRef
8.
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21:349–53.PubMed
9.
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4.PubMedCrossRef
10.
Bomanji JB, Papathanasiou ND. 111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S113-125.PubMedCrossRef
11.
Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25:272–8.PubMedCrossRef
12.
Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506.PubMedCrossRef
13.
Chin R-I, Wu FS, Menda Y, Kim H. Radiopharmaceuticals for neuroendocrine tumors. Semin Radiat Oncol. 2021;31:60–70.PubMedCrossRef
14.
Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun. 2008;29:283–90.PubMedCrossRef
15.
Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136–43.PubMedCrossRef
16.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.PubMedCrossRef
17.
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–34.PubMedCrossRef
18.
Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22.PubMedPubMedCentralCrossRef
19.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41.PubMedPubMedCentralCrossRef
20.
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.PubMedCrossRef
21.
Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)–a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510–8.PubMedCrossRef
22.
Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9–15.PubMedCrossRef
23.
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295–309.PubMedCrossRef
24.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.PubMedPubMedCentralCrossRef
25.
Myrehaug S, Singh S, Pavel M, Kunz P, De Herder W, Herrmann K, et al. 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study. Radiother Oncol. 2022;174:S40–1.CrossRef
26.••
Singh S, Halperin DM, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. JCO. 2024;42:LBA588–LBA588. Preliminary results of the NETTER-2 study, presented at the ASCO GI 2024 that show the potential of PRRT as first-line therapy.CrossRef
27.
Rodrigues M, Svirydenka H, Virgolini I. Theragnostics in Neuroendocrine Tumors. PET Clin. 2021;16:365–73.PubMedCrossRef
28.
Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23-29.PubMedCrossRef
29.
Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.PubMedPubMedCentralCrossRef
30.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.PubMedCrossRef
31.
Anbari Y, Veerman FE, Keane G, Braat AJAT, Smits MLJ, Bruijnen RCG, et al. Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer. J Interv Med. 2023;6:153–9.PubMedPubMedCentral
32.
Ramdhani K, Braat AJAT. The evolving role of radioembolization in the treatment of neuroendocrine liver metastases. Cancers (Basel). 2022;14:3415.PubMedCrossRef
33.
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60.PubMedCrossRef
34.
Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Phys. 2021;8:77.PubMedPubMedCentralCrossRef
35.
Ebbers SC, van Roekel C, Braat MNGJA, Barentsz MW, Lam MGEH, Braat AJAT. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. Eur J Nucl Med Mol Imaging. 2022;49:1700–10.PubMedCrossRef
36.
Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of radioembolization in metastatic neuroendocrine tumors. Cardiovasc Intervent Radiol. 2022;45:1590–8.PubMedCrossRef
37.
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372–82.PubMedPubMedCentralCrossRef
38.
Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663–9.PubMedCrossRef
39.
Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21:561–70.PubMedCrossRef
40.
Ramdhani K, Smits MLJ, Lam MGEH, Braat AJAT. Combining selective internal radiation therapy with immunotherapy in treating hepatocellular carcinoma and hepatic colorectal metastases: a systematic review. Cancer Biother Radiopharm. 2023;38:216–24.PubMed
41.
Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - chemotherapy. Neuroendocrinology. 2017;105:281–94.PubMedCrossRef
42.
43.
Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology. 2016;103:432–9.PubMedCrossRef
44.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48:3260–7.PubMedPubMedCentralCrossRef
45.
Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, et al. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). BJR. 2018;91:20170172.PubMedPubMedCentralCrossRef
46.•
Chan DS, Kanagaratnam AL, Pavlakis N, Chan DL. Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: a systematic review. J Neuroendocrinol. 2023;e13355. https://​doi.​org/​10.​1111/​jne.​13355. An extensive systematic review on combined PRRT and chemotherapy.
47.
Di Santo G, Santo G, Sviridenko A, Virgolini I. Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023. Theranostics. 2024;14:940–53.PubMedPubMedCentralCrossRef
48.
Claringbold PG, Turner JH. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): a phase I study. Cancer Biother Radiopharm. 2015;30:261–9.PubMed
49.
50.
Kleibeuker EA, ten Hooven MA, Verheul HM, Slotman BJ, Thijssen VL. Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis. 2015;18:385–95.PubMedPubMedCentralCrossRef
51.
Nonnekens J, van Kranenburg M, Beerens CEMT, Suker M, Doukas M, van Eijck CHJ, et al. Potentiation of Peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6:1821–32.PubMedPubMedCentralCrossRef
52.
Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard J-M, et al. Optimizing the schedule of PARP inhibitors in combination with 177Lu-DOTATATE: a dosimetry rationale. Biomedicines. 2021;9:1570.PubMedPubMedCentralCrossRef
53.
Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, et al. Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020;10:10196.PubMedPubMedCentralCrossRef
54.
Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S. Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment. Clin Cancer Res. 2022;28:3652–7.PubMedPubMedCentralCrossRef
55.
Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8:e000980.PubMedPubMedCentralCrossRef
56.
Barber TW, Hofman MS, Thomson BNJ, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64–71.PubMedCrossRef
57.
van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0, Tyr3]octreotate. J Nucl Med. 2015;56:1647–53.PubMedCrossRef
58.
Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, Grana CM, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163:761–7.PubMedCrossRef
59.
Parghane RV, Bhandare M, Chaudhari V, Ostwal V, Ramaswamy A, Talole S, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2021;62:1558–63.PubMedPubMedCentralCrossRef
60.
Minczeles NS, van Eijck CHJ, van Gils MJ, van Velthuysen M-LF, Nieveen van Dijkum EJM, Feelders RA, et al. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur J Nucl Med Mol Imaging. 2022;49:3203–14.PubMedPubMedCentralCrossRef
61.•
Siebinga H, Hendrikx JJMA, de Vries-Huizing DMV, Huitema ADR, de Wit-van der Veen BJ,. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2024;51:820–7. This study clearly quantifies the reduction in tumor uptake as treatment with PRRT continues. Highlighting the importance of the first two cycles of PRRT.PubMedCrossRef
62.
Roth D, Gustafsson J, Warfvinge CF, Sundlöv A, Åkesson A, Tennvall J, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177 Lu-DOTATATE. J Nucl Med. 2022;63:399–405.PubMedPubMedCentralCrossRef
63.
Jahn U, Ilan E, Sandström M, Lubberink M, Garske-Román U, Sundin A. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers. 2021;13:962.PubMedPubMedCentralCrossRef
64.
Fazio N, Falconi M, Foglia E, Bartolomei M, Berruti A, D’Onofrio M, et al. Optimising radioligand therapy for patients with gastro-entero-pancreatic neuroendocrine tumours: expert opinion from an Italian Multidisciplinary Group. Adv Ther. 2024;41:113–29.PubMedCrossRef
65.
Cutler CS, Bailey E, Kumar V, Schwarz SW, Bom H-S, Hatazawa J, et al. Global issues of radiopharmaceutical access and availability: a nuclear medicine global initiative project. J Nucl Med. 2021;62:422–30.PubMedPubMedCentralCrossRef
Metadata
Title
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
Authors
Denise S. Hoogenkamp
Linda J. de Wit–van der Veen
Daphne M. V. Huizing
Margot E. T. Tesselaar
Rachel S. van Leeuwaarde
Marcel P. M. Stokkel
Marnix G. E. H. Lam
Arthur J. A. T. Braat
Publication date
10-04-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01521-w

Other articles of this Issue 5/2024

Current Oncology Reports 5/2024 Go to the issue

ReviewPaper

Ovarian Suppression: Early Menopause, Late Effects

REVIEW

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

REVIEW

Immune Checkpoint Inhibitors in Geriatric Oncology

REVIEW

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

REVIEW

Perioperative Neurocognitive Function in Glioma Surgery

REVIEW

Patient Navigation in Cancer Treatment: A Systematic Review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits